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Abstract
Cerebral amyloid angiopathy (CAA) is a common but often asymptomatic disease, characterized by deposition of
amyloid in cerebral blood vessels. We describe the successful treatment of CAA encephalopathy with dexametha-
sone in a patient with CAA-related inflammation causing subacute progressive encephalopathy and seizures, which
is an increasingly recognized subtype of CAA. The two pathological subtypes of CAA-related inflammation are
described and a review of the literature is performed concerning immunosuppressive treatment of CAA-related
inflammation with special attention to its pathological subtypes. Immunosuppressive therapy appears to be an
appropriate treatment for CAA encephalopathy.
Background
Sporadic cerebral amyloid angiopathy (CAA) is a com-
mon but often asymptomatic neuropathological finding,
characterized by the deposition of amyloid-b (Ab)i n
small and medium-sized cerebral arteries, arterioles and
sometimes capillaries of the meninges and brain parench-
yma. Its prevalence is strongly associated with increasing
age and has been reported to be as high as 57% percent
in case series of asymptomatic patients over 60 years of
age [1]. CAA is a common finding in patients with Alz-
heimer’s disease (AD); but many patients with CAA do
not develop AD. CAA can lead to lobar haemorrhage in
non-hypertensive patients [2]. Other, less often reported
clinical manifestations are seizures, transient neurological
deficits and dementia other than AD [3]. In addition,
more rare presentations have been reported, including
space occupying lesions and leukoencephalopathy on
magnetic resonance imaging (MRI) [4-6]. The latter is an
increasingly recognized syndrome encompassing suba-
cute encephalopathy, headache, seizures or focal neurolo-
gical symptoms. Upon brain biopsy, an inflammatory
process is found in relation to the vascular deposits of
Ab. In contrast to other Ab-depositing disorders such as
AD, immunosuppressive treatment has been reported to
ameliorate both clinical and radiological symptoms of
CAA encephalopathy, although with variable success [7].
This variability could be explained by the existence of dif-
ferent underlying pathological subtypes. We describe a
patient with CAA-leukoencephalopathy, who was treated
successfully with dexamethasone. We also performed a
literature review concerning the use of immunosuppres-
sive treatment for CAA-related inflammation with special
attention to its pathological subtypes.
Case presentation
A 74-year-old man with an unremarkable medical his-
tory noted a progressive gait disorder in the months
prior to admission. His wife recalled increased sleepiness
and loss of initiative. After having seizures the patient
was admitted to our hospital. The patient was disorien-
tated in time and did not perform complicated tasks,
although this could partly be attributed to apathy. He
could not remember the reason for his stay in the hos-
pital. The remaining neurological examination revealed
no abnormalities. MRI showed confluent bifrontal white
matter lesions and minimal enhancement of the white
matter in the right frontal lobe after administration of
gadolinium (Figure 1A-D). Routine laboratory measure-
ments were normal. Cerebral spinal fluid examination
revealed an elevated protein level (1.78 g/l). No malig-
nant cells were found in the spinal fluid. After diagnos-
tic work-up had excluded a primary tumour elsewhere
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bri was considered and a stereotactic brain biopsy was
performed. Histopathological analysis showed extensive
Ab immunopositivity around smaller and larger blood
v e s s e l s( F i g u r e2 A ,B ) .N on e u r o f i b r i l l a r yt a n g l e so r
amyloid plaques were found in the parenchyma. Reac-
tive gliosis, strong upregulation of microglia and multi-
ple macrophages around the blood vessels in both white
and grey matter were present (Figure 2C, D). The find-
ings were compatible with sporadic CAA. After the
patient developed progressive apathy, loss of initiative,
magnetic gait and hypertonia of the extremities,
treatment with dexamethasone (2 × 4 mg/day) was
started. There was a remarkable clinical improvement in
the following days. The patient became alert, the hyper-
tonia disappeared and he was able to walk with a
wheeled walker. After 5 weeks, he was discharged from
the hospital with a mild gait disorder. A 3 Tesla MRI
three months after admission showed remarkable ameli-
oration of the white matter abnormalities. Gradient
echo sequences showed subcortical hypointensities,
compatible with multiple microbleeds (figure 1). Dexa-
methasone treatment was tapered in the months after
admission.
Figure 1 Axial MRI at presentation (A, B) and 3 months after treatment (C, D). A) Contrast enhanced, T1- weighted image shows low
signal intensity of the right frontal lobe with minimal enhancement of the white matter (white arrowhead). B) T2-weighted image shows high
signal intensity in the right frontal lobe. C) Gradient echo sequence shows subcortical ‘black dots’, consistent with microbleeds (white arrows),
and a small postoperative hematoma after biopsy. D) T2-weighted image after treatment shows a decrease of high signal intensity in the right
frontal lobe.
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The clinical picture of CAA-related inflammation includes
encephalopathy, seizures and headaches. Extensive vaso-
genic edema and/or leukoencephalopathy is visible on
MRI, sometimes mimicking space-occupying lesions. His-
tological examination shows amyloid-laden vessels and the
appearance of Ab in close association with inflammatory
cells, implicating Ab as the potential trigger for the inflam-
matory response. It remains unclear why only a few CAA
patients develop this response. A high percentage of
such patients are homozygous for the ε4-allele of the apo-
lipoprotein E gene (APOE ε4/ε4; 76.9% vs 5.1% in non-
inflammatory CAA) [6], which is associated with activation
of complement and microglia. Additionally, trials of anti-
Ab vaccination in patients with Alzheimer’s disease (AD)
induced similar clinical, radiological and pathological
inflammation as seen in CAA-related inflammation, sug-
gesting an immune response to Ab.
Unlike other Ab-depositing disorders, CAA-associated
inflammation appears to derive a beneficial effect from
corticosteroid treatment. This effect could be depen-
dant on the pathological subtype of CAA-related
inflammation.
Two subtypes of CAA-associated inflammation have
been described so far: (i) a non-vasculitic form called
perivascular infiltration (PVI), which is characterized by
perivascular infiltration of the parenchyma by multinu-
cleated giant cells and (ii) a vasculitic form called trans-
mural (non)-granulomatous angiitis (TGA), which is
characterized by inflammation of the vessel wall with
the occasional presence of granulomas. Both pathologic
forms can co-occur, suggesting at least a partial overlap
[8]. The clinical and radiological findings of both var-
iants are remarkably similar. Our case showed reactive
gliosis and multiple macrophages around blood vessels
in grey and white matter, although no multinucleated
cells were seen. This is consistent with reactive edema
in encephalopathy and suggests PVI. Although often
called CAA-angiitis, the terms CAA-vasculopathy or
CAA-encephalopathy are preferred, since these terms do
Figure 2 Cytological and histological examination of biopsy. A) Smear slide showing amyloid (metachromatic, purple) around a capillary
(toluidin blue stain), B) paraffin-embedded material: extensive amyloid deposition around capillaries in cortex (Ab immunoreaction), C) reactive
gliosis and upregulation of microglia and macrophages in grey matter, D) reactive gliosis, upregulation of microglia and presence of
macrophages in white matter (C and D, HLA-DR (CR3/43) immunoreaction).
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Author n Age Pathology Radiology Therapy Clinical
improvement
Radiological
improvement
Follow-
up
Clinical
features
Comments
Ginsberg 1988
[10]
1 73 TGA Confluent Dx, Pn Yes Yes >1 year Gait disturbance
Mandybur 1992
[11]
1 62 TGA Mass CP, Pn Yes Yes Death 8
months
Encephalopathy
Focal neurology
Hallucinations
Remarkable
pathological
improvement lesions
post-mortem
compared to initial
biopsy
Osumi 1995 [4] 1 59 ? Mass CS No ? Death 5
months
Focal neurology
Headaches
Seizures
Silbert 1995 [12] 1 74 ? Confluent Dx No No Death 6
weeks
Headache
Seizures
Fountain 1996
[13]
1 66 TGA Confluent CP, Dx,
Pn,
No Partial 20
months
Encephalopathy
Headaches
Seizures
Fountain 1996
[13]
1 69 TGA Confluent CP, Dx,
Pn,
Partial Partial Death 6
months
Encephalopathy
Headaches
Seizures
Relapse
Ortiz 1996 [14] 1 68 PVI Mass Dx, Pn Yes Yes ? Encephalopathy
Gait disturbance
Headaches
Masson 1998
[15]
1 64 PVI Confluent CP, Pn Yes No 15
months
Encephalopathy
Headaches
Fountain 1999
[16]
1 71 PVI, TGA Confluent CP Yes Yes 22
months
Encephalopathy
Gait disturbance
Headaches
Relapse after stop CP
Streichenberger
1999 [17]
1 67 TGA Mass/
Confluent
CS Yes Yes Death 1
month
Headaches
Encephalopathy
Hoshi 2000 [18] 1 65 - (after
treatment)
Recurrent
ICH
Pn Yes NA 6
months
Focal neurology
Schwab 2003
[19]
1 74 PVI/TGA Mass Dx 1m,
Pn
Yes ? 12
months
Encephalopathy
Headaches
Seizures
Schwab 2003
[19]
1 70 PVI//TGA Mass Pn, CP Partial Yes 18
months
Encephalopathy
Headaches
Seizures
Oh 2004 [20] 1 80 PVI Confluent Dx, Pn Yes Yes 8
months
Encephalopathy
Focal Neurology
Seizures
1 patient with no
therapy excluded
Oh 2004 [20] 1 77 TGA Confluent Dx, Pn Yes Yes 6 weeks Encephalopathy
Focal Neurology
Seizures
1 patient with no
therapy excluded
Safriel 2004 [5] 1 49 TGA Mass Dx, tap
6 weeks
Yes Partial 9
months
Seizures
Scolding 2005
[21]
7 69* TGA Confluent Pn, Dx,
CP
43% ? 58
months*
Encephalopathy
Focal Neurology
Headaches
Seizures
2 patients excluded
because of mass
resection as therapy
Kinnecom 2007
[6]
12 63.2
±1 0
PVI Confluent CS, CP 83% 83% 47
months*
Encephalopathy
Headache
Seizures
25% relapse, 33% died
McHugh 2007
[9]
1 80 PVI, TGA Confluent Pn Yes Yes 24
months
Encephalopathy
Focal Neurology
Seizures
Machida 2008
[22]
1 69 PVI Confluent Dx, Pn Yes Yes 12
months
Encephalopathy
Focal neurology
Relapsing/remitting
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perivascular inflammation [8].
Because of various reports regarding success of corti-
costeroid treatment, we performed a literature review on
the use of immunosuppressive agents in CAA-encepha-
lopathy with special attention to its pathological sub-
types. A total of 45 patients in 18 articles could be
identified (Table 1) [4-6,8-22]. In four patients TGI and
PVI co-occurred [8,15,18]. Corticosteroids were the
most commonly used drugs, varying from short, high-
dosage intravenous treatments to continuous treatment
with low-dose prednisone. One case report reported
effective treatment with low dose cyclophosmamid alone
[16]. Similar to our case, there were generally favourable
outcomes in most patients after immunosuppressive
treatment. Clinical and radiological symptoms were
(partly) reversed in 76% of all patients, although some
experienced relapses during follow-up.
Although publication bias, small study numbers and
the possible self-limiting nature of the disease has to be
taken into account, the quick response to immunosup-
pressive therapy and the tendency to relapse in drug-
free periods suggest a beneficial effect of immunosup-
pressants. In general, patients with TGA did not benefit
as much as patients with PVI [68% vs 88%]: possibly the
v a s c u l i t i cf o r mg i v e sr i s et om o r ei s c h e m i cl e s i o n s
(reflected in the higher proportion of focal deficits in
this group) than in PVI, in which there could be more
vasogenic edema.
It is interesting that only CAA encephalopathy
responds to corticosteroid treatment, in contrast to
other Ab-depositing disorders. A possible explanation
could be that corticosteroids merely reduce cerebral
vasogenic edema. However, in vitro research has shown
that dexamethasone diminishes the pro-inflammatory
and cytotoxic effects of Ab in cerebrovascular smooth
muscle cells in later stages of the inflammation process,
although it does not affect initial Ab deposition [23].
This suggests a direct effect upon the pathogenesis of
acute inflammation in Ab-disorders, as it is found in
CAA encephalopathy. In any case, our review shows
there is a possible role for the use of corticosteroids in
patients with CAA encephalopathy.
Conclusions
CAA encephalopathy is an increasingly recognized syn-
drome that is based upon a vasculitic or non-vasculitic
inflammatory reaction to Ab. Although the clinical and
radiological symptoms are similar in both pathologic
variants, immunosuppressive therapy appears to have a
slightly less beneficial effect in the vasculitic subtype.
Nevertheless, corticosteroid therapy seems to be an
appropriate therapy for both. In an elderly patient with
a subacute progressive encephalopathy with seizures,
CAA-related encephalopathy has to be considered
because of the major therapeutical implications.
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